• Deferoxamine Mesylate: Precision Iron Chelation for Ferropto

  2026-05-21

  Explore how Deferoxamine mesylate, a leading iron-chelating agent, enables next-generation ferroptosis and oxidative stress studies through precise modulation of iron metabolism. Uncover unique insights into NRF2 pathway interactions and advanced assay design.

• Diclofenac: Non-Selective COX Inhibitor in Intestinal Organo

  2026-05-20

  Unlock the power of Diclofenac, a high-purity non-selective COX inhibitor, to model human inflammation and drug metabolism using hiPSC-derived intestinal organoids. This guide translates cutting-edge protocols into actionable steps, highlighting troubleshooting strategies and APExBIO’s reliable product performance for advanced pharmacokinetic and pain signaling research.

• BI 2536: PLK1 Inhibitor Workflows for Cancer Research Excell

  2026-05-20

  BI 2536 enables precise cell cycle and apoptosis studies, setting the gold standard for PLK1 inhibitor use in both in vitro and in vivo cancer models. This guide details robust workflows, troubleshooting, and experimental insights to maximize the impact of BI 2536 in translational oncology.

• Translating Apoptosis Detection: Annexin V-FITC/PI in Focus

  2026-05-19

  This thought-leadership article bridges mechanistic insight and strategic guidance for translational researchers, exploring the role of the Annexin V-FITC/PI Apoptosis Assay Kit in elucidating cell death pathways, benchmarking its utility in the context of nanoparticle-induced lung injury, and offering actionable recommendations for high-impact apoptosis research.

• HPF for Highly Reactive Oxygen Species Detection in Cell Ass

  2026-05-19

  HPF (hydroxyphenyl fluorescein) sets the benchmark for specific, quantitative detection of highly reactive oxygen species in cell biology and cancer research. This guide details actionable workflows, troubleshooting, and advanced use-cases leveraging HPF’s unmatched selectivity and performance for intracellular oxidative stress visualization.

• Lanabecestat (AZD3293): Optimizing BACE1 Inhibition for Safe

  2026-05-18

  Explore how Lanabecestat (AZD3293) enables precise, synaptic-sparing amyloid-beta reduction in Alzheimer’s disease research. This article uniquely examines safe dosing strategies, mechanistic insights, and practical workflow optimizations for BACE1 inhibition.

• Ruxolitinib (INCB018424): Advanced Protocols in Myeloprolife

  2026-05-18

  Ruxolitinib (INCB018424) redefines immunomodulation studies in myeloproliferative disorder research by enabling high-dimensional immune profiling and precision JAK-STAT pathway interrogation. This guide delivers actionable protocol enhancements, troubleshooting insights, and a practical translation of cutting-edge spectral cytometry findings for robust, reproducible results.

• ATRX-Deficient Glioma Cells: Enhanced Sensitivity to RTK/PDG

  2026-05-17

  This study demonstrates that ATRX-deficient high-grade glioma cells exhibit pronounced sensitivity to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. The findings support incorporating ATRX status in clinical trial analyses and highlight implications for targeted therapy and combinatorial approaches in glioma research.

• Anti-ROR1 Antibody (Zilovertamab): Advancing Functional Canc

  2026-05-16

  Explore how Anti-ROR1 Antibody (Zilovertamab) empowers functional assays and translational cancer research by enabling precise Wnt5a-induced ROR1 signaling inhibition. This article uniquely bridges molecular mechanism, practical assay optimization, and emerging insights from mitophagy research.

• Tunable Human Intestinal Organoid System Enables Balanced Se

  2026-05-15

  This study presents a robust protocol for generating human intestinal organoids with enhanced cellular diversity and proliferative capacity, overcoming longstanding limitations in balancing stem cell self-renewal and differentiation. By systematically modulating key signaling pathways with small molecules, the authors establish a scalable and tunable culture platform with significant implications for organoid-based research and high-throughput applications.

• FerroOrange: Fe²⁺ Fluorescent Probe for Live Cell Iron Detec

  2026-05-15

  FerroOrange empowers researchers with real-time, selective detection of intracellular Fe²⁺, enabling high-resolution iron metabolism and ferroptosis studies. Its streamlined protocol, live-cell specificity, and compatibility with fluorescence microscopy and flow cytometry offer unmatched flexibility for both basic and translational research.

• Mechanisms of Spiroplasma eriocheiris Entry into Drosophila

  2026-05-14

  Wei et al. (2019) reveal that Spiroplasma eriocheiris invades Drosophila S2 cells primarily via clathrin-mediated endocytosis and macropinocytosis, leading to apoptosis and decreased cell viability. These findings clarify pathogen entry routes in invertebrate models and highlight cytoskeletal and endocytic pathways as potential intervention points.

• PLGA-Based Nano-Adjuvant Boosts Mucosal Immunity in Chicks

  2026-05-14

  This study introduces a PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that significantly enhances both mucosal and systemic immune responses against H9N2 avian influenza in chicks. Through targeted intestinal delivery and sustained antigen release, it addresses the limitations of traditional vaccine adjuvants, supporting improved vaccine efficacy.

• Annexin V-FITC/PI Apoptosis Assay Kit: Protocol and QC Guide

  2026-05-13

  The Annexin V-FITC/PI Apoptosis Assay Kit (SKU K2003) provides a rapid, fluorescence-based workflow for distinguishing apoptotic stages in mammalian cells. It is best suited for research applications requiring early apoptosis detection or cell death pathway analysis using flow cytometry or fluorescence microscopy. The kit is not intended for diagnostic or clinical use and should not be used outside the recommended cell types and detection platforms.

• Paroxetine Mesylate: Multi-Target Mechanisms and Oncology Pr

  2026-05-13

  Explore the advanced pharmacological mechanisms of Paroxetine Mesylate, a selective serotonin reuptake inhibitor, and its emerging role as a multi-target agent in oncology. This article delivers a unique, evidence-based perspective that bridges molecular pharmacology with translational cancer research.

484 records 13/33 page Previous Next First page 上5页 1112131415 下5页 Last page